CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings

/in /by

Skeletal muscle index measured from regular CT scans works as a simple marker to predict outcomes and treatment response in newly diagnosed hormone-sensitive prostate cancer, based on this STAMPEDE study review. Low muscle, or sarcopenia, is common in advanced prostate cancer and gets worse with hormone therapy, but skeletal muscle index (SMI) uses psoas muscle […]

Read more

Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC

/in , , , /by

Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. ​Eighty-four patients enrolled […]

Read more

UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer

/in , , , /by

The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]

Read more

Early Results From a Phase 1 Trial for MRT-2359 Plus Enzalutamide in mCRPC

/in , , , /by

MRT-2359 is a daily pill that destroys certain cancer-driving proteins, including the androgen receptor (AR), MYC, and Cyclin D1, by blocking a key step in how cells read genetic instructions. This approach targets metastatic castration-resistant prostate cancer (mCRPC), where AR mutations in the ligand-binding domain (LBD) allow tumors to grow despite hormone-blocking drugs like enzalutamide. […]

Read more

Phase 1 PAnTHa Trial: mCRPC First Data

/in , , /by

²²⁵Ac‑PSMA‑Trillium (BAY3563254) is an experimental treatment that delivers targeted alpha radiation to prostate cancer cells. It combines a highly selective PSMA‑binding molecule with an albumin‑binding domain that helps it stay in the bloodstream longer and reach tumors more effectively. The radioactive component, actinium‑225, is attached using a stable Macropa chelator to increase safety and stability. […]

Read more

BRCAAway OS Update: Abiraterone + Olaparib Extends Survival by 5 Years in HRRm mCRPC

/in , , /by

The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic […]

Read more

pre|CISION Platform Update: AVA6103 Outperforms Leading ADC, Phase 1 Dosing Imminent

/in , /by

Since October 2025, when the pre|CISION platform first demonstrated its potential to deliver dual payloads like MMAE and exatecan from a single molecule in prostate cancer models, significant new data has emerged that strengthens its case as a next-generation targeted therapy. The platform’s ability to exploit fibroblast activation protein (FAP) in the tumor microenvironment for […]

Read more

UPDATE: SECuRE Trial, Another Complete Responder

/in , , /by

A striking new update from the ongoing SECuRE trial has revealed yet another participant achieving undetectable PSA levels alongside a completely negative PSMA PET scan, underscoring the potential of 67Cu-SAR-bisPSMA in advanced prostate cancer treatment. This 76-year-old patient, facing progressive metastatic castration-resistant prostate cancer (mCRPC) 15 years after initial diagnosis, started with a baseline PSA […]

Read more